ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy, Chairman and Tim Franklin, Chief Operating Officer join Proactive London's Katie Pilbeam to explain the latest market update in respect of its late stage Lupus drug, Lupuzor.
The key highlight is that Lupuzor is scheduled to start the phase III trial in second half of this year. The update followed guidance proffered by the US regulator after its interaction in December with Avion Pharmaceuticals, which is leading the development of the drug.